Not available
Quote | Cellectis Romainville Ord (OTCMKTS:CMVLF)
Last: | $2.60 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $2.60 |
High: | $0 |
Low: | $0 |
Volume: | 40 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Cellectis Romainville Ord (OTCMKTS:CMVLF)
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new ...
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that preliminary data exp...
Message Board Posts | Cellectis Romainville Ord (OTCMKTS:CMVLF)
Subject | By | Source | When |
---|---|---|---|
$CMVLF recent news/filings | stocktrademan | investorshub | 04/12/2015 2:44:22 PM |
$CMVLF recent news/filings | stocktrademan | investorshub | 08/19/2014 3:18:38 PM |
Stock_Tracker: Latest Cellectis Romainvil (CMVLF) Headlines Cellectis and Servier announce collabora | Stock_Tracker | investorshangout | 03/09/2014 2:20:48 PM |
chartguy89: CMVLF 6.70 Stock Charts $CMVLF 1 Month Chart | chartguy89 | investorshangout | 03/06/2014 5:59:13 PM |
Stock_Tracker: CMVLF Recent News Cellectis and Servier announce collaboration in allogeneic cell the | Stock_Tracker | investorshangout | 03/04/2014 9:54:30 PM |
News, Short Squeeze, Breakout and More Instantly...
Cellectis Romainville Ord Company Name:
CMVLF Stock Symbol:
OTCMKTS Market:
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new ...
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that preliminary data exp...
NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it h...